Carltonhelms2869

Background Drug-eluting beads transarterial chemoembolization (DEB-TACE) has emerged as an alternative to conventional transarterial chemoembolization (cTACE) for treatment of hepatocellular carcinoma (HCC), although selection between the approaches remains controversial. Objective To compare patients with unresectable HCC treated with DEB-TACE and cTACE in terms of hepatobiliary changes on imaging and clinical complications. Methods This retrospective study included 1002 patients (871 men, 131 women; mean age, 59±12 years) from three centers with treatment-naïve unresectable HCC who underwent 780 DEB-TACE using epirucibin (780 procedures in 394 patients) and 1187 cTACE using lipiodol mixed with doxorubicin and oxaliplatin (1187 procedures in 608 patients) between May 2016 and November 2018. buy LY364947 A total of 83.4% of patients had hepatitis B related liver disease; 57.6% were Barcelona Clinic Liver Cancer (BCLC) stage A or B; 42.4% had ≥3 nodules. Mean tumor size was 6.3±4.2 cm. Hepatobiliary changes and tumor response were evaluated on CT or MRI 1 month after TACE. Clinical records were reviewed for adverse events. Results Bile duct dilation and portal vein narrowing on imaging, as well as liver failure and grade 3 abdominal pain on clinical follow-up, all had higher frequency (p.05), although overall DCR was higher in cTACE than DEB-TACE (1 month 87.5% vs 80.0%, p=.001; 3 months 78.5% vs 72.1%, p=.02). Conclusion Compared with cTACE, DEB-TACE was associated with more frequent hepatobiliary injuries and severe abdominal pain. Clinical impact Greater caution and closer follow-up are warranted for patients who undergo DEB-TACE for unresectable HCC.

To evaluate the use of transarterial chemoembolisation (TACE) combined with microwave ablation (MWA) to treat patients with hepatocellular carcinoma (HCC) and type Ⅱ-Ⅲ portal vein tumour thrombosis (PVTT) intolerant to targeted drug (TG) therapy.

A total of 18 patients with HCC and type Ⅱ-Ⅲ PVTT intolerant to TG were enrolled between June 2015 and December 2019, who were treated with TACE + MWA (MWA group). 24 patients were treated with TACE + TG (TG group; control cohort). Time to progression and overall survival (OS) were analysed along with the incidence of adverse events.

The median follow-up time was 19.0 months (9.0-32.0 months). The median OS was 17.0 months (8.3-29.3 months; MWA group) and 13.5 months (5.5-22.5 months; TG group) and was not significantly different. The 1- and 2 year OS was also comparable (MWA group 66.7%, 44.4%

Target group 41.7%, 29.2%). Time to progression showed no distinct differences (MWA group 11.5 months; TG group 9.0 months) between the two groups. Moreover, the incidence of major Grade 3-4 adverse events in the MWA group (5.6%) was similar to those in the TG group (8.3%).

TACE + MWA and TACE + TG were comparable in their safety and efficacy in patients with HCC, type Ⅱ-Ⅲ PVTT, and intolerance to TG.

TACE + MWA can be used as a palliative treatment alternative for TACE + TG in patients with HCC, type Ⅱ-Ⅲ PVTT, and intolerance to TG.

TACE + MWA can be used as a palliative treatment alternative for TACE + TG in patients with HCC, type Ⅱ-Ⅲ PVTT, and intolerance to TG.This study examined whether relationships with family, friends, and neighbors (both satisfaction and number in the social network) were associated with older women's well-being concurrently and over two years. Additionally, age differences among older women were explored. Women aged 60+ (N = 224, Mage = 80) were sampled from the Social Integration and Aging Study. Greater family and friend satisfaction were positively associated with well-being; number in network was not. Age-related effects for family and friend relationships suggested potential protective effects for the oldest women. Findings highlight unique facets of older women's relationships, suggesting future directions addressing age and support source.Diabetic cardiovascular diseases (DCVDs) are the most common complications of diabetes mellitus and are considered to be one of the most important threats to global health and an economic burden. Long noncoding RNA (lncRNA), circular RNA (circRNA), and miRNA are a novel group of noncoding RNAs that are involved in the regulation of various pathophysiological processes, including DCVDs. Interestingly, both lncRNA and circRNA can act as competing endogenous RNA of miRNA, thereby regulating the expression of the target mRNA by decoying or sponging the miRNA. In this review, we focus on the mechanistic, pathological and functional roles of lncRNA/circRNA-miRNA-mRNA networks in DCVDs and further discuss the potential implications for early detection, therapeutic intervention and prognostic evaluation.Severe fever with thrombocytopenia syndrome virus (SFTSV) is a novel bunyavirus. Since 2007, SFTS disease has been reported in China with high fatality rate up to 30%, which drew high attention from Centre for Disease Control and Prevention and government. SFTSV is endemic in the centra l and eastern China, Korea and Japan. There also have been similar cases reported in Vietnam. The number of SFTSV infection cases has a steady growth in these years. As SFTSV could transmitted from person to person, it will expose the public to infectious risk. In 2018 annual review of the Blueprint list of priority diseases, World Health Organisation has listed SFTSV infection as prioritised diseases for research and development in emergency contexts. However, the pathogenesis of SFTSV remains largely unclear. Currently, there are no specific therapeutics or vaccines to combat infections of SFTSV. This review discusses recent findings of epidemiology, transmission pathway, pathogenesis and treatments of SFTS disease.

To compare CT-guided transthoracic cutting needle biopsy (TCNB) with transthoracic aspiration needle biopsy (TANB) for pulmonary lesions with respect to the diagnostic accuracy and complication rate.

Of the 859 cases that underwent consecutive CT-guided biopsy of pulmonary lesions, 713 cases confirmed by surgical pathology or clinical follow-up were enrolled. Of these, the first consecutive 275 cases underwent TANB, and the remaining 438 received TCNB. The final diagnosis determined the accuracy of biopsy. Based on the post-biopsy CT and clinical medical records, the presence or absence of biopsy-related complications was determined. The χ

test was used to compare the differences between TCNB and TANB in terms of diagnostic accuracy and complication rate.

Among the 713 biopsy lesions, the final diagnosis was malignant in 411 cases and benign in 302 cases. As compared to TANB, the diagnostic accuracy of TCNB (98.9%

93.8%, χ

= 14.35,

< 0.01), sensitivity to malignant lesions (97.8%

90.6%, χ

= 10.